Innoviva, Inc. (NASDAQ:INVA) Shares Purchased by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. raised its stake in Innoviva, Inc. (NASDAQ:INVA) by 10.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,274 shares of the biotechnology company’s stock after purchasing an additional 1,241 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Innoviva were worth $230,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Martingale Asset Management L P boosted its holdings in Innoviva by 0.7% in the third quarter. Martingale Asset Management L P now owns 77,842 shares of the biotechnology company’s stock valued at $1,503,000 after acquiring an additional 550 shares during the last quarter. US Bancorp DE lifted its stake in shares of Innoviva by 24.5% in the 3rd quarter. US Bancorp DE now owns 2,875 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 566 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Innoviva by 18.5% during the 3rd quarter. GAMMA Investing LLC now owns 4,119 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 643 shares during the period. FMR LLC increased its position in Innoviva by 8.2% during the 3rd quarter. FMR LLC now owns 10,119 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 771 shares in the last quarter. Finally, KBC Group NV raised its holdings in Innoviva by 73.9% in the fourth quarter. KBC Group NV now owns 4,100 shares of the biotechnology company’s stock valued at $71,000 after buying an additional 1,743 shares during the period. 99.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, StockNews.com downgraded shares of Innoviva from a “buy” rating to a “hold” rating in a research note on Tuesday, December 31st.

Innoviva Trading Down 1.4 %

Shares of INVA opened at $18.64 on Monday. Innoviva, Inc. has a 12 month low of $14.32 and a 12 month high of $21.28. The stock’s 50-day moving average is $18.30 and its two-hundred day moving average is $18.88. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.79 and a quick ratio of 1.64. The stock has a market cap of $1.17 billion, a PE ratio of 27.01 and a beta of 0.54.

Innoviva (NASDAQ:INVA) last released its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.27 by ($0.25). Innoviva had a return on equity of 20.84% and a net margin of 18.31%. The company had revenue of $89.51 million for the quarter. Equities analysts forecast that Innoviva, Inc. will post 0.33 earnings per share for the current fiscal year.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.